PF-06700841 tosylate Chemical Properties

Boiling point:

637.1±65.0 °C(Predicted)

Density 

1.63±0.1 g/cm3(Predicted)

storage temp. 

room temp

solubility 

DMSO: 78 mg/mL (200.31 mM);Ethanol: 78 mg/mL (200.31 mM)

form 

powder

pka

7.28±0.10(Predicted)

color 

white to beige

Water Solubility 

Water: Insoluble

PF-06700841 tosylate Usage And Synthesis

Chemical Properties

The p-toluenesulfonic acid salt of brepocitinib exhibits good aqueous solubility (4.84 mg/mL at pH 7.64; >7 mg/mL in simulated gastric fluids). This compound also displayed high passive membrane permeability (mean PAPP = 18.8 × 10?6 cm/s as determined using Ralph Russ canine kidney cells (RRCK)).

Characteristics

Class: non-receptor tyrosine kinase
Treatment: immunological disorders
Other name: PF-06700841; Brepocitinib
Elimination half-life = 3.8–7.5 h
Protein binding = 39%

Uses

PF-06700841 tosylate salt has been used as an inhibitor of Janus kinase1 (JAK1) to study its therapeutic effect on the adjuvant induced arthritis (AIA) rat model. It has also been used as an inhibitor of interferon-α/β receptor alpha chain (IFNAR1) signaling adaptor tyrosine kinase (2TYK2) in mice.

Biochem/physiol Actions

PF-06700841 prevents IL-23 (interleukin 23) signaling through TYK2 (Tyrosine-protein kinase 2)/JAK1 (Janus kinase 1) inhibition.

Pharmacokinetics

The high oral bioavailability of brepocitinib obtained from rats (83%) is consistent with its high passive permeability and good solubility. The elimination half-life of brepocitinib ranged from 3.8 to 7.5 h after a single oral dose and from 4.9 to 10.7 h after multiple-dose administration. It was eliminated from the body by CYP450-mediated hepatic metabolism (84%) (mainly via CYP3A4) and renal clearance (16%). Oxidation of the N-methyl pyrazole (2) is the major metabolic pathway, followed by N-demethylation (3) and N-dealkylation with loss of pyrazole (4).

PF-06700841 tosylate(1883299-62-4)Related Product Information

• PF-6274484
• PF-9366
• 4-[(Diethylamino)methyl]-N-[2-(2-methoxyphenyl)ethyl]-N-(3R)-3-pyrrolidinylbenzamide
• 3-(5-fluoro-indol-3-yl)-pyrrolidine-2,5-dione
• PF-06447475
• 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one
• Lorlatinib (PF-06463922)
• PF-06700841-TsOH
• PF-06282999
• PF 4618433
• PF-06650833
• PF-6260933
• 5-PyriMidinecarboxaMide, 4-[(2-Methylpropyl)aMino]-N-(phenylMethyl)-2-[4-[(tetrahydro-2H-pyran-3-yl)Methyl]-1-piperazinyl]-
• PF-01247324
• PNU 100480
• PF 05175157
• Ketohexokinase inhibitor 1
• PF-562271